Prolonged chimeric antigen receptor‐T apheresis to infusion time is associated with inferior outcomes in diffuse large B‐cell lymphoma
British Journal of Haematology · 2025-10 · 207 (4) · 1484-1494
DOI: 10.1111/bjh.70090 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 11.08.2025. Verfasst von Suguru Morimoto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Kyoto University Hospital, Kyoto, Japan. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Blood Component Removal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T‐cell therapy is effective for relapsed/refractory (r/r) diffuse large B‐cell lymphoma (DLBCL). However, delays between apheresis and infusion frequently occur due to limited facility capacity and prolonged bridging therapy, and the clinical impact of such delays remains uncertain. We retrospectively analysed R/R DLBCL patients who underwent CAR‐T‐cell therapy at Kyoto University Hospital. Among 90 patients, the median apheresis to infusion interval was 66 days (range, 28–203). Patients were categorized into delayed (≥66 days) and non‐delayed (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Kyoto University Hospital, Kyoto, Japan.
- Department of Cytotherapy, Kyoto University Hospital, Kyoto, Japan.
- Center for Research and Application of Cellular Therapy, Kyoto University Hospital, Kyoto, Japan.
- Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
ORCID-Profile: Tomoyasu Jo, Toshio Kitawaki, Junya Kanda, Momoko Nishikori, Yasuyuki Arai
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Morimoto, S., Jo, T., Kitawaki, T., Sakamoto, T., Mizumoto, C., Kanda, J., Nishikori, M., Yamashita, K., Nagao, M., Takaori-Kondo, A., & Arai, Y. (2025). Prolonged chimeric antigen receptor‐T apheresis to infusion time is associated with inferior outcomes in diffuse large B‐cell lymphoma. British Journal of Haematology, 207(4), 1484-1494. https://doi.org/10.1111/bjh.70090
Vancouver
Morimoto S, Jo T, Kitawaki T, Sakamoto T, Mizumoto C, Kanda J, et al. Prolonged chimeric antigen receptor‐T apheresis to infusion time is associated with inferior outcomes in diffuse large B‐cell lymphoma. British Journal of Haematology. 2025;207(4):1484-1494. doi:10.1111/bjh.70090
BibTeX
@article{Morimoto2025,
author = {Morimoto, Suguru and Jo, Tomoyasu and Kitawaki, Toshio and Sakamoto, Takashi and Mizumoto, Chisaki and Kanda, Junya and Nishikori, Momoko and Yamashita, Kouhei and Nagao, Miki and Takaori-Kondo, Akifumi and Arai, Yasuyuki},
title = {Prolonged chimeric antigen receptor‐T apheresis to infusion time is associated with inferior outcomes in diffuse large B‐cell lymphoma},
journal = {British Journal of Haematology},
year = {2025},
volume = {207},
number = {4},
pages = {1484--1494},
doi = {10.1111/bjh.70090}
}
EUVIMED